Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer.

CONCLUSIONS: The GRsig discovered herein identifies high-risk ER-negative/GR-positive BCs most likely to relapse despite administration of adjuvant chemotherapy. Because GR antagonism can reverse expression of these genes, we propose that addition of a GR antagonist to chemotherapy may improve outcome of these high-risk patients. PMID: 29636357 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29636357?dopt=Abstract

Source: Clinical Cancer Research - April 10, 2018 Category: Cancer & Oncology Authors: West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Győrffy B, Con Tags: Clin Cancer Res Source Type: research